Novo Nordisk stock gains analyst support as Wegovy wins China approval

Published on 09/10/2026 at 14:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novo Nordisk stock is trading below its 52-week high while HSBC on September 10, 2026 raised its target to DKK 320 and kept a Hold stance. Wegovy also secured approval in China for treating MASH on September 10, 2026, adding a new growth leg beyond obesity.

Flatlay mit Spritze, Teststreifen, Notizbuch und Apfel auf weißem Untergrund — Novo Nordisk A/S (DK0062498333): Flatlay mit Spritze, Blutzucker-Teststreifen, Notizbuch und Apfel auf Weiß, Illustration mit AI erstellt.

Novo Nordisk A/S stock (ISIN DK0062498333) is trading below its recent highs even as the Danish healthcare group secures fresh support from analysts and a new regulatory milestone for its obesity drug Wegovy as of September 10, 2026. According to price data from Nasdaq Copenhagen, the B share last closed at around DKK 288.90, leaving a visible gap to the average analyst price target of DKK 310.17.

HSBC lifts price target on Novo Nordisk stock

As of September 10, 2026, one of the key catalysts for Novo Nordisk stock is a target hike from HSBC that underscores both upside potential and lingering caution. According to Zonebourse on September 10, 2026, HSBC increased its price target on Novo Nordisk from DKK 300 to DKK 320 while maintaining its recommendation at Hold, with the shares having last closed at DKK 288.90 on Nasdaq Copenhagen. The new target therefore implies upside of about 11 percent from that closing level, while the consensus average target of DKK 310.17 points to a narrower potential gain of 7.36 percent.

The same analyst overview shows that Novo Nordisk is currently covered by 24 analysts, with a consensus recommendation of Hold and an average target of DKK 310.17 at the time of publication. According to Zonebourse, that average target of DKK 310.17 sits about 7.36 percent above the DKK 288.90 closing price on Nasdaq Copenhagen, underlining that the stock is seen as having moderate further room to rise rather than deep undervaluation.

Wegovy approval in China broadens growth story

Alongside the analyst action, a fresh regulatory decision in China adds a strategic angle to Novo Nordisk stock. On September 10, 2026, Wegovy was approved in China as the first drug in the GLP-1 receptor agonist class to treat metabolic dysfunction-associated steatohepatitis, or MASH, extending its reach beyond weight loss. According to Devdiscourse on September 10, 2026, Wegovy became the first GLP-1 RA drug approved in China to treat MASH, with the company highlighting that the decision broadens Wegovy’s benefits from weight and cardiovascular management to liver health.

This approval reinforces Novo Nordisk’s position in the fast-growing market for obesity and metabolic disease treatments. As Devdiscourse notes, Wegovy’s newly recognised role in managing liver health adds a further dimension to its potential, since MASH is one of the complications closely linked to obesity and metabolic dysfunction. For investors, that means the drug’s addressable market in China now extends beyond patients seeking weight reduction to those with advanced fatty liver disease, strengthening the long-run revenue narrative.

Recent earnings and fundamentals frame valuation

The current valuation of Novo Nordisk stock is also informed by its most recent reported financial figures. According to an earnings summary on June 30, 2026, cited by MarketBeat, Novo Nordisk generated quarterly revenue of USD 11.98 billion and earnings per share of USD 0.94 in that reporting period, with a net margin of 35.36 percent. The same overview states that the company achieved a trailing twelve-month return on equity of 61.20 percent, reflecting high capital efficiency and profitability.

Those figures position Novo Nordisk as one of the more profitable large-cap healthcare names. According to MarketBeat, the company’s market capitalization stands at about USD 201.60 billion, with a trailing price-to-earnings ratio of roughly 11.04 and a price-to-book ratio near 6.86. Taken together with the consensus price target of USD 64.94 versus a current New York price around USD 45.15 cited in the same source, analysts on that venue see upside of approximately 43.8 percent for the American depositary shares, although the overall rating is still only Hold.

Risks: clinical setbacks temper enthusiasm

Despite the strength of Wegovy’s franchise and high profitability, Novo Nordisk stock is not without risks, some of which have surfaced in recent days. According to the analyst and news overview on Zonebourse, Novo Nordisk has recently halted two clinical trials for its experimental cardiovascular drug ziltivekimab, a move that clouds its growth prospects outside obesity. In the same news stream, Barclays lowered its target price on Novo Nordisk from DKK 310 to DKK 300 and reiterated an equal-weight stance, signalling more cautious expectations for the stock even as HSBC’s higher target offers a counterpoint.

These developments illustrate the delicate balance underlying Novo Nordisk stock at current levels. On one hand, the core obesity and diabetes franchises, including Wegovy, Ozempic and other semaglutide-based treatments, continue to deliver strong growth and new indications such as MASH in China. On the other hand, setbacks in cardiovascular pipelines and mixed analyst views mean the valuation hinges on continued flawless execution in the obesity segment and successful expansion of approved indications, rather than a broad range of new therapeutic areas.

Novo Nordisk stock trades below targets

From a market perspective, Novo Nordisk’s primary listing on Nasdaq Copenhagen provides the reference price for investors. As reported in the analyst consensus overview on Zonebourse, Novo Nordisk B shares last closed at DKK 288.90 on Nasdaq Copenhagen on September 9, 2026, with the stock changing by about minus 1.06 percent on that day and standing roughly 11.18 percent below its level at the start of 2026. With the average target of DKK 310.17 and HSBC’s new DKK 320 target both above that close, the share price currently trades in the lower part of its target range and below the implied fair values from the main analyst houses.

For investors, the key question is whether Wegovy’s expansion into liver disease treatment in China and continued strength in obesity can outweigh the clinical setbacks and the Hold consensus to close that gap to the targets. At a Copenhagen closing price of DKK 288.90 as of September 9, 2026, Novo Nordisk stock offers measured potential toward both the consensus target of DKK 310.17 and HSBC’s higher DKK 320 estimate, while its strong margins and high return on equity support the case for the company as a leading, though not risk-free, player in global metabolic disease treatment.